Art. -Nr.: HY-125662A

BMX-001

Name: BMX-001
Brand: MedChemExpress
SKU: HY-125662A
Price: 505.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Kundenbewertung

Based on 1 Customer Validation

BMX-001 is a blood-brain barrier-penetrant, redox-active manganese porphyrin SOD mimetic with reactive oxygen species/reactive nitrogen species scavenging activity. BMX-001 inhibits NF-κB through S-glutathionylation, activates Nrf2/Keap1, and decreases TRPV1. BMX-001 enhances glucose-stimulated insulin secretion and inhibits islet apoptosis. BMX-001 radiosensitizes tumors, reduces cancer-associated fibroblasts, promotes dendritic cell maturation, modulates macrophage/MDSC/T cell responses, inhibits EMT/angiogenesis/hypoxia/inflammation, and induces apoptosis. BMX-001 protects glial cells while exerting pro-oxidant effects in cancer, and alleviates neuropathic pain. BMX-001 has neuroprotective effects in ischemic stroke. BMX-001 can be used for research on type 1 diabetes, ischemic stroke, pain, breast cancer, and glioblastoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 98%
CAS. Nr.: 1379783-91-1
Formel: C₆₄H₇₆Cl₅MnN₈O₄
Molecular Weight:1253.54

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

BMX-001 Chemical Structure

CAS. Nr.: 1379783-91-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle TRP Channel Isoform-spezifische Produkte anzeigen :

In Vitro

Anti-cancerCytokines & ChemokinesOxidative StressCarbohydrate MetabolismApoptosisOthers

Anti-cancer

Cytokines & Chemokines

Oxidative Stress

BMX-001 selectively kills LN-229 glioblastoma cells while sparing NHA normal human astrocytes, and reduces TNF-α and MnSOD in NHA cells after irradiation at 48 h^[5].

Carbohydrate Metabolism

Apoptosis

BMX-001 (34 μM; 24 h) reduces mouse islet apoptosis; improves glucose-stimulated insulin secretion in mouse islets, with a stimulation index of 4.1^[1].

Oxidative Stress

BMX-001 (0.25-0.5 μM; 24 h) acts as a ROS scavenger in primary mouse SGCs, reducing PTX-induced total ROS; in MDA-MB-231 cells, it exerts a pro-oxidant effect, increasing PTX-induced ROS^[4].
BMX-001 (0.25-0.5 μM; 24 h) preserves catalase and GPx activity in primary mouse SGCs while reducing PTX-induced SOD activity; in MDA-MB-231 cells, it impairs the antioxidant enzyme defense system under PTX-induced stress^[4].

Others

BMX-001 (50 µg/mL) does not alter t-PA-mediated clot lysis in an ex vivo rat arterial clot lysis assay^[2].
BMX-001 co-incubation inhibits PTX-induced TNF-α and increases Nrf2 expression in primary mouse SGCs; it downregulates NF-κB expression in MDA-MB-231 cells without reducing PTX-induced TNF-α^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[4]

Cell Line:

MDA-MB-231 human triple-negative breast cancer cells
Concentration:

0, 0.1, 0.25, 0.5, 1, 2 μM
Incubation Time:

24 h
Result:

For MDA-MB-231, 0.25 μM BMX-001 and 0.5 μM PTX were selected as safe concentrations for subsequent in vitro experiments based on cytotoxicity tests.

In Vivo

Anti-cancerApoptosisAdaptive ImmunityInnate ImmunityCytokines & ChemokinesImmune Tolerance & ImmunosuppressionCarbohydrate MetabolismOxidative StressOthers

Anti-cancer

Apoptosis

Adaptive Immunity

Innate Immunity

Cytokines & Chemokines

Immune Tolerance & Immunosuppression

BMX-001 (1 mg/kg; intraperitoneal injection; twice weekly; monotherapy or combined with radiotherapy at 2 Gy X-rays daily for three consecutive days) alone does not significantly inhibit 4T1 tumor growth in female BALB/c mice, but reduces the CAF population and modulates the proportions of T cell subsets; combined administration reduces 4T1 tumor volume in female BALB/c mice and promotes antitumor immunity and tumor microenvironment changes, including an increase in Cd8_Tem, a decrease in Cd4_Treg, and reduced T cell dysfunction^[3].

Carbohydrate Metabolism

BMX-001 (34 µM; cultured in medium for 24 hours) improves engraftment of marginal human islet xenografts in immunodeficient B6-RAG^-/- mice during human islet culture^[1].

Carbohydrate Metabolism

Cytokines & Chemokines

Apoptosis

BMX-001 (10-34 µM; pancreatic distension/islet isolation and 24-hour culture) improves engraftment of marginal syngeneic islet transplants under the renal capsule of BALB/c mice during mouse islet isolation and culture^[1].

Oxidative Stress

BMX-001 (0.5 mg/kg; subcutaneous injection; on days 1, 3, 5, and 7, followed by twice weekly on days 9, 11, 15, and 18) in combination alleviates PTX-induced mechanical and thermal hyperalgesia and reduces neuroinflammation and oxidative stress markers in the DRG of CINP mice; the single agent does not alter mechanical or thermal sensitivity in healthy mice^[4].

Others

BMX-001 (30-225 µg/kg; subcutaneous injection after intracarotid administration; twice daily; 7 days) improves 7-day neurological deficits and reduces infarct volume in young male and female Wistar stroke rats^[2].
BMX-001 (50-225 µg/kg; subcutaneous injection after intra-arterial administration; twice daily; 7 days) improves 28-day neurological functional recovery in young and aged stroke rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c (8-12 weeks old male donors; BALB/c recipients)^[1]
Dosage:

10 µM and 34 µM
Administration:

supplemented during pancreas distension/islet isolation; 24-h culture
Result:

Improved marginal syngeneic islet engraftment under the kidney capsule in BALB/c mice, with 58% of recipients receiving 34 µM-supplemented islets becoming euglycemic.

Animal Model:

B6-RAG^-/- (B6.129S7-Rag1tm1Mom/J)^[1]
Dosage:

34 µM
Administration:

supplemented in culture medium; 24 h
Result:

Improved marginal human islet xenograft engraftment in immunocompromised B6-RAG^-/- mice, with 92.3% of recipients receiving 34 µM-supplemented islets achieving euglycemia.

Animal Model:

Wistar (Hsd:WI, male, 250-275 g, 9 weeks old; female, 225-250 g, 9 weeks old)^[2]
Dosage:

30 µg/kg; 225 µg/kg
Administration:

intra-carotid infusion over 5 min immediately after reperfusion; s.c. twice daily for 7 days
Result:

Improved 7-day neurological deficits and reduces infarct volume in young Wistar stroke rats.

Animal Model:

SHR (male, 225-250 g, 8 weeks old)
Fisher 344 (female, 220-250 g, 22 months old)^[2]
Dosage:

50 µg/kg; 225 µg/kg
Administration:

intra-carotid infusion immediately after reperfusion; s.c. twice daily for 7 days
Result:

Improved 28-day neurological functional recovery.

Animal Model:

C57BL/6 (female, 56-62 days old, 18-21 g)^[4]
Dosage:

0.5 mg/kg per dose (BMX-001); 8 mg/kg (PTX)
Administration:

BMX-001: s.c. on Days 1, 3, 5, and 7, then twice weekly on Days 9, 11, 15, and 18; PTX: i.p. on Days 1, 3, 5, and 7
Result:

Alleviated mechanical allodynia in CINP mice upon co‑administration of PTX and BMX‑001 in von Frey test.
Mitigated PTX‑evoked cold allodynia in acetone test and PTX‑induced thermal allodynia in hotplate test following combined PTX and BMX‑001 treatment.
Reduced PTX‑triggered upregulation of TRPV1, reversed elevated TNF‑α signal, and inhibited increased IBA‑1 expression in DRG tissues upon BMX‑001 intervention, with quantitative immunofluorescence intensity differences detected across experimental groups.
Prevented PTX‑mediated TNF‑α upregulation, boosted Nrf2 expression and suppressed PTX‑driven TRPV1 overexpression at DRG transcriptional level by BMX‑001 in qPCR assays, whereas PTX elevated TNF‑α and IL‑6 transcripts.

Related Protocols :

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991			2011-05	PHASE1

Chemical Information

CAS. Nr. 1379783-91-1
Appearance Solid
Molecular Weight 1253.54
Formel C₆₄H₇₆Cl₅MnN₈O₄
Color Brown to black
SMILES

CCCCOCC[N+]1=C(C=CC=C1)C2=C3C=CC4=C(C5=[N+](CCOCCCC)C=CC=C5)C6=[N]7[Mn+3]8([N-]34)[N-]9C(C(C%10=[N+](C=CC=C%10)CCOCCCC)=C%11C=CC2=[N]8%11)=CC=C9C(C%12=[N+](CCOCCCC)C=CC=C%12)=C7C=C6.[Cl-].[Cl-].[Cl-].[Cl-].[Cl-]
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (19.94 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.7977 mL

3.9887 mL

7.9774 mL

5 mM

0.1595 mL

0.7977 mL

1.5955 mL

10 mM

0.0798 mL

0.3989 mL

0.7977 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (323 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Bruni A, et al. BMX-001, a novel redox-active metalloporphyrin, improves islet function and engraftment in a murine transplant model. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2018 Aug;18(8):1879-1889. [Content Brief]

[2]. Pan T, et al. Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. Pharmaceuticals. 2025 Aug 5;18(8):1159.

[3]. Noh SU, et al. Single-Cell Profiling Reveals Immune-Based Mechanisms Underlying Tumor Radiosensitization by a Novel Mn Porphyrin Clinical Candidate, MnTnBuOE-2-PyP (BMX-001). Antioxidants (Basel, Switzerland). 2024 Apr 17;13(4):477.

[4]. Pan T, et al. Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. Pharmaceuticals (Basel, Switzerland). 2025 Aug 05;18(8):1159.

[5]. Li X, et al. Intracarotid Infusion of Redox-Active Manganese Porphyrin, MnTnBuOE-2-PyP5+, following Reperfusion Improves Long-Term, 28-Day Post-Stroke Outcomes in Rats. Antioxidants. 2023 Oct 13;12(10):1861.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.7977 mL	3.9887 mL	7.9774 mL	19.9435 mL
	5 mM	0.1595 mL	0.7977 mL	1.5955 mL	3.9887 mL
	10 mM	0.0798 mL	0.3989 mL	0.7977 mL	1.9944 mL
	15 mM	0.0532 mL	0.2659 mL	0.5318 mL	1.3296 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BMX-001

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle TRP Channel Isoform-spezifische Produkte anzeigen